Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Nicotine replacement therapy · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | ACTIVE_COMPARATOR | Standard NRT user direction |
| 2 | EXPERIMENTAL | Novel NRT user direction |
| Name | Type | Description |
|---|---|---|
| Nicotine replacement therapy | DRUG | Nicotine replacement therapy with Standard NRT user direction |
Inclusion Criteria: * 18 years or older male and female cigarette smokers motivated and willing to stop smoking * female participants of child-bearing potential should use a medically acceptable means of birth control * evidence of a personally signed and dated informed consent document indicating ...
Nicotine replacement therapy is used for smoking cessation. It is a small molecule being developed by Johnson & Johnson (JNJ) for this indication. The therapy is currently in Phase 2 clinical development, with one completed trial involving 258 participants in the United Kingdom.
Johnson & Johnson (JNJ) is developing Nicotine replacement therapy. The therapy is a small molecule intended for smoking cessation. It is currently in Phase 2 clinical development, with one completed trial that enrolled 258 participants.
Nicotine replacement therapy is in Phase 2 clinical development. It is an investigational therapy for smoking cessation and has not been approved by regulatory authorities. One Phase 2 trial has been completed, involving 258 participants in the United Kingdom.
Nicotine replacement therapy has one completed clinical trial, NCT00764439, titled 'Pilot Study of a New Nicotine Replacement Therapy'. This Phase 2 trial enrolled 258 participants with smoking cessation as the condition, was conducted in the United Kingdom, and included adults aged 18 years and older.
Nicotine replacement therapy is a specific investigational product being developed by Johnson & Johnson. It is not described as being the same as any other named product. The therapy is in Phase 2 development for smoking cessation, with one completed trial.